Navigation Links
HIV integrase inhibitor effective for patients beginning antiretroviral treatment
Date:8/2/2009

A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.

The results are online and scheduled for publication in an upcoming issue of the Lancet.

Lead author of the Lancet article is Jeffrey Lennox, MD, professor of medicine (infectious diseases) at Emory University School of Medicine. Lennox is chief of Emory's HIV/AIDS clinical trials unit and vice-chair of medicine dealing with Grady Memorial Hospital.

"These results provide an additional potent, well tolerated treatment option for newly diagnosed patients with HIV infection," says Lennox.

Raltegravir, a HIV integrase inhibitor, is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor, the researchers found. Raltegravir also had faster onset of action and fewer adverse side effects. In the clinical trial, both were combined with two other standard retroviral drugs, tenofovir and emtricitabine.

The trial included 566 patients from 67 medical centers on five continents. The "primary endpoint" of the trial was pushing viral levels below 50 copies per ml of blood by week 48. Of the raltegravir group, 86 percent reached that goal, compared with 82 percent of the efavirenz group.

Half the raltegravir group reached the endpoint by week four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encountered fewer side effects such as headache, dizziness and elevation in levels of cholesterol.

Raltegravir inhibits the HIV integrase enzyme, which inserts the viral genome into the host cell's DNA. It was the first integrase inhibitor to be approved by the FDA. Other types of antiretroviral drugs inhibit HIV's protease or reverse transcriptase enzymes.

Guidelines from the U.S. Department of Health and Human Services currently recommend efavirenz or a protease inhibitor, in combination with tenofovir and emtricitabine, as a preferred drug regimen for adults beginning antiretroviral treatment.

Efavirenz, tenofovir and emtricitabine make up a once-a-day combination (Atripla) approved by the FDA in 2006. The authors note that raltegravir is usually taken twice a day, which may be more difficult for some patients. However, raltegravir's reduction in side effects and concerns about the ability of efavirenz to cause birth defects may be advantages for raltegravir, the authors say.

Raltetravir was approved by the FDA in 2007, but at first only for people infected with HIV that is resistant to other drugs. The results of this study contributed to the July 2009 decision by the FDA to expand the indication for raltegravir beyond only individuals infected with HIV that is resistant to other drugs.


'/>"/>

Contact: Sarah Goodwin
sgoodwi@emory.edu
404-727-3366
Emory University
Source:Eurekalert

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
10. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
11. ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
(Date:1/19/2017)... ... 2017 , ... The CHP suggests that California drivers can avoid hydroplaning as ... and increasing the space between themselves and other vehicles, according to a January 3 ... R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017  Hoy, ... lanzaron Access Accelerated, una iniciativa global para avanzar el ... y atención en países de renta baja y baja-media ... alcanzado un punto de crisis, particularmente en países de ... 80 por ciento de las muertes relacionadas con NCD. ...
Breaking Medicine Technology: